MyFinsight
Home
Blog
About
Sales and maturities
of marketable...
$34,000K
(-72.94%↓ Y/Y)
Net cash provided by
investing activities
$33,810K
(18.08%↑ Y/Y)
Canceled cashflow
$190K
Net change in cash,
cash equivalents and...
$1,848K
(108.66%↑ Y/Y)
Canceled cashflow
$31,962K
Purchases of property and
equipment
$190K
(-74.15%↓ Y/Y)
Product revenue
allowances
$18,761K
(467.66%↑ Y/Y)
Accounts payable and
other liabilities
$10,204K
(-39.86%↓ Y/Y)
Stock-based compensation
$2,107K
(-58.50%↓ Y/Y)
Intangible asset
amortization
$1,987K
(-43.28%↓ Y/Y)
Right-of-use asset
amortization
$1,451K
Other non-cash
adjustments, net
-$490K
(83.03%↑ Y/Y)
Depreciation of property and
equipment
$267K
(-46.39%↓ Y/Y)
Net cash used in
operating activities
-$31,070K
(35.80%↑ Y/Y)
Net cash used in
financing activities
-$856K
(51.06%↑ Y/Y)
Effect of exchange rate
changes on cash, cash...
-$36K
(-119.67%↓ Y/Y)
Canceled cashflow
$35,267K
Net loss
-$62,513K
(-10.25%↓ Y/Y)
Principal payments on
finance leases
$856K
(2.64%↑ Y/Y)
Accounts receivable
$2,802K
(228.47%↑ Y/Y)
Prepaid expenses and
other assets
$885K
(-87.03%↓ Y/Y)
Inventory
$97K
(-95.63%↓ Y/Y)
Amortization of premiums and
accretion of discounts on...
$40K
(-96.93%↓ Y/Y)
Back
Back
Cash Flow
Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. (VNDA)
source: myfinsight.com